% | $
Quotes you view appear here for quick access.

aTyr Pharma Inc. Message Board

  • rosemariecorbin rosemariecorbin Feb 10, 2012 7:07 AM Flag

    ILMN is getting the attention while LIFE is getting the sales

    A 13% improvement in the Ion Torrent-centric genetic systems segment.
    LIFE calculated its revenue rather conservatively, with non-GAAP earnings clocking in $40 million below GAAP results. Even without that downward adjustment, Life Tech still set new revenue records, besting the $941 million earned in 2011's second quarter.

    2011 free cash flow was $710 million on revenue of $3.7 billion.
    Non-GAAP organic revenue should grow by 2% to 4% in 2012, with the company issuing EPS guidance between $3.90 and $4.05.
    Life Tech revenue grew 2% in the Americas, 3% in Europe, and 9% in the Asia-Pacific region last year. Japanese revenue declined 3% on the year.
    E-commerce sales grew 12% in 2011. Over half the company's transactions are now processed through this platform.
    CEO Greg Lucier compared Life Tech's e-commerce platform to, noting that his company can ship bio-active products anywhere in the world within five days.
    Life Tech now has 900 employees in the Chinese region (including Taiwan and Hong Kong) and plans to add another 250 this year.
    Despite having $2.3 billion in long-term debt, Life Tech remains committed to a $300 million share repurchase, which comes on top of $100 million already spent on repurchases in just the past six months.
    Life Tech has $882 million in the bank -- plenty to meet this goal.
    Government and academic customers will be "challenged, but stable."
    The Ion Torrent sequencing platform should "grow significantly."
    The breakneck drop in sequencing costs and its potential for broad adoption. The Ion Torrent segment only generated $278 million in fourth-quarter revenue, about a quarter of Life Tech's total.
    Costs are going down LIFE is going up

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.94-0.07(-2.33%)Aug 25 4:00 PMEDT